Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Total Current Liabilities (2016 - 2025)

Amicus Therapeutics' Total Current Liabilities history spans 16 years, with the latest figure at $237.8 million for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 59.94% year-over-year to $237.8 million, compared with a TTM value of $237.8 million through Dec 2025, up 59.94%, and an annual FY2025 reading of $237.8 million, up 59.94% over the prior year.
  • Total Current Liabilities for Q4 2025 was $237.8 million at Amicus Therapeutics, up from $198.9 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $237.8 million in Q4 2025, with the low at $99.7 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $154.3 million, with a median of $155.5 million recorded in 2024.
  • Year-over-year, Total Current Liabilities fell 11.32% in 2024 and then surged 59.94% in 2025.
  • Tracing FOLD's Total Current Liabilities over 5 years: stood at $146.0 million in 2021, then dropped by 4.77% to $139.0 million in 2022, then rose by 20.62% to $167.7 million in 2023, then decreased by 11.32% to $148.7 million in 2024, then surged by 59.94% to $237.8 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Total Current Liabilities are $237.8 million (Q4 2025), $198.9 million (Q3 2025), and $167.6 million (Q2 2025).